医疗保健技术公司GoodRx Holdings,Inc.(GDRX)今日盘中股价大跌23%。尽管公司上季度营收实现了8.5%的同比增长,但财报显示其调整后每股收益为0.08美元,低于华尔街分析师平均预期的0.09美元。
分析人士指出,GoodRx公司近期业绩增长乏力,且盈利能力未能达到预期,这可能是导致投资者对该公司前景观望、大量抛售股票的主要原因。数据显示,GoodRx股价本季度已下跌12%,全年迄今为止亦下跌近9%。
值得注意的是,尽管GoodRx本季度业绩略逊预期,但该公司业务整体保持平稳运营。分析师目前给予GoodRx股票的平均评级为"买入",认为公司在医疗技术领域的长期增长潜力仍然可期。不过,考虑到公司近期业绩增长放缓,投资者对其未来表现的担忧情绪或将持续,短期内股价恐难有起色。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.